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Abstract
Background: No study has explored the risk of metabolic syndrome (MS) in patients with epilepsy treated with valproate
(VPA) at the population level. The aim of this study was to compare the risk of MS in VPA-treated patients in Estonia to the
risk in the general population.
Methods: This study involved 118 patients with epilepsy (63 men, 55 women) who received VPA monotherapy. MS was
diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III criteria. Data were compared
with the results of a population-based study of the prevalence of MS in the same geographic region (N = 493; 213 men, 280
women).
Results: In the multiple logistic regression analysis, after adjustment for age and sex, the risk of MS in VPA-treated patients
was not increased compared to the control subjects (odds ratio [OR] = 1.00; 95% confidence interval [CI], 0.59–1.68). VPA-
treated patients had higher serum insulin concentrations than control subjects, independent of body mass index (BMI). A
positive association was found between MS development and BMI (OR = 1.47; 95% CI, 1.25–1.73) in VPA-treated patients,
but there were no associations with the VPA dosage or the homeostasis model assessment-estimated insulin resistance
(HOMA-IR) index. In control subjects, BMI and HOMA-IR had similar predictive abilities for MS occurrence. In VPA-treated
patients, the predictive ability of the HOMA-IR index was significantly lower than that of BMI, with areas under the receiver
operating characteristic curves of 0.808 and 0.897 (P = 0.05), respectively.
Conclusions: The risk of MS is not increased among VPA-treated patients with epilepsy in Estonia compared to the general
population. The HOMA-IR index likely has a lower predictive ability for MS in VPA-treated patients compared to its predictive
ability in the general population.
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Introduction
Valproate (VPA) is one of the most frequently used antiepileptic
drugs worldwide [1]. It is currently widely applied for other
indications as well, such as bipolar disorder and migraine
prophylaxis [2]. In many cases, the duration of treatment may
be long, which emphasizes the importance of the long-term safety
of the drug. One of the most common side effects of VPA
treatment is weight gain, which occurs in about half of patients
and is associated with important metabolic and endocrine
abnormalities [3]. VPA treatment is also associated with elevated
serum insulin levels and changes in the levels of triglycerides (TG)
and high-density lipoprotein cholesterol (HDL-C) [4].
In 1988, Reaven described metabolic syndrome (MS) as a
cluster of metabolic conditions, including glucose intolerance,
dyslipidemia, central obesity, and hypertension, which are major
risk factors for cardiovascular and cerebrovascular diseases [5].
The worldwide prevalence of MS in the adult population has been
reported to be about 24.7–28.8% [6–10]. In a recent population-
based study, the estimated prevalence of MS in Estonia was 27.9%
[11]. Although many studies have explored the problem of obesity
in VPA-treated patients, the presence of MS among them has
received little attention. Verrotti at al. [12] found that the
prevalence of MS in children and adolescents treated with VPA
who became obese was similar to that observed in otherwise
healthy overweight subjects. However, another study found that
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obese patients with epilepsy who were treated with VPA were at
higher risk of developing MS than obese control subjects [13].
No study to date has explored the risk of MS in VPA-treated
patients at the population level. Thus, the aim of our study was to
evaluate the prevalence of MS and its components in VPA-treated




The study was carried out in the Departments of Neurology and
Internal Medicine, Tartu University Hospital, Estonia, between 1
January and 31 December 2012. This hospital is a tertiary referral
center for southern Estonia. Distributions of the ethnic groups and
the socioeconomic status of inhabitants are similar among the
various counties in southern Estonia.
Using the prescription database of the Estonian Health
Insurance Fund, patients with epilepsy from six southern Estonian
counties who were prescribed VPA in 2011 were identified.
Exclusion criteria for patients with epilepsy were as follows: age $
18 years; VPA monotherapy for .3 months; polytherapy with
other antiepileptic drugs; pregnancy; and severe physical or
mental disability. In particular, patients who lived at nursing
homes or who were dependent at home or outside the home were
excluded. Only patients who were able to engage in normal
occupational and social activities, despite minor physical or mental
deficits, were included in the study. Patients with endocrine
disturbances, such as diabetes or thyroid dysfunction, were not
excluded.
The control group comprised subjects who participated in a
population-based cross-sectional multicenter study of MS preva-
lence conducted in southern Estonia between November 2008 and
May 2009. Control subjects were adults who were randomly
selected from four general practices. An invitation letter about the
study was sent to each participant. The total response rate was
53.2% (493 control subjects). The control subjects were represen-
tative of the general Estonian population in terms of age and
gender.
Collection of anthropometric and laboratory data
The first and second author, respectively, interviewed and
clinically examined all patients and control subjects. The medical
histories of participants were documented during the evaluation
meeting. Concomitant diseases of relevance to the study, including
known endocrinopathies, lipid metabolism disorders, and vascular
diseases, were noted. Blood pressure (BP), waist circumference,
weight, and height were measured, and body mass index (BMI)
was calculated as weight (in kg) divided by height squared (in m2).
Blood samples were obtained in the morning (between 08:00 and
11:00) after an overnight fast ($10 h) for the analysis of serum
insulin, HDL-C, TG, and plasma glucose concentrations. Patients’
serum VPA concentrations were also measured.
During face-to-face interviews, patients’ epilepsy diagnoses were
re-evaluated, and the date of the last seizure was recorded.
Seizures and epileptic syndromes were classified based on the
recently proposed International League against Epilepsy classifi-
cation [14]. In patients with classical idiopathic generalized
epilepsy syndromes resulting directly from a known or presumed
genetic defect(s), the etiology of epilepsy was classified as
‘‘genetic’’. The date of initiation, duration, and current dosage
of VPA treatment were recorded. Patients were asked whether
they had noticed any change in body weight after initiation of
VPA treatment. The Ethics Review Committee on Human
Research of Tartu University approved the study. All participants
provided written informed consent.
Assays
Plasma glucose levels were measured by the hexokinase method.
HDL-C and TG concentrations were measured by an enzymatic
colorimetric assay. VPA concentrations were measured by
fluorescence polarization assay (COBAS INTEGRA 800 Plus
Analyzer; Roche, Basel, Switzerland). In control subjects, plasma
insulin concentrations were measured by a chemiluminescent
assay (Immulite 2000 Analyzer; Siemens Healthcare Diagnostics,
Deerfield, IL, USA), whereas in patients, they were measured by
an electrochemiluminescent assay (COBAS 6000 Analyzer;
Roche). To compare plasma insulin concentrations between
cohorts, the bias between the two measurement assays was
calculated according to the Clinical and Laboratory Standards
Institute’s guidelines [15].
Definition of metabolic syndrome
MS was diagnosed based on the presence of at least three of the
following National Cholesterol Education Program Adult Treat-
ment Panel III criteria [16]: waist circumference $102 cm in men
and $88 cm in women, BP$130/85 mmHg or antihypertensive
medication use, fasting glucose concentration $5.6 mmol/L or
previously diagnosed diabetes, TG concentration $1.7 mmol/L
or lipid-regulating medication use, and HDL-C concentration ,
1.03 mmol/L in men and ,1.3 mmol/L in women or drug
treatment for reduced HDL-C. Insulin resistance (IR) was
estimated by the homeostasis model assessment-estimated insulin
resistance (HOMA-IR) index, calculated with the following
equation: fasting glucose (mmol/L)6fasting insulin (mU/L)/22.5.
Patients with BMIs$25 kg/m2 were categorized as overweight.
Statistical analysis
Descriptive analytical methods, such as the calculation of
means, standard deviations (SDs), medians, and interquartile
ranges (IQRs), were used for continuous variables, depending on
the distribution. Age- and sex-adjusted linear regression models
were used to compare anthropometric and laboratory data
between VPA-treated patients and control subjects. Multiple
logistic regression analysis was performed to identify factors
associated with MS development in VPA-treated patients and
control subjects. The final model included only significant factors.
A receiver operating characteristic (ROC) analysis was conducted
to evaluate whether BMI and HOMA-IR had similar predictive
abilities for MS in both cohorts. The prevalence of MS in VPA-
treated patients was calculated by the indirect method of
standardization, considering the age and sex distribution of the
control group as the standard. Odds ratios (ORs) and 95%
confidence intervals (95% CIs) are reported. The R software
package (The R Foundation for Statistical Computing; version
2.15.1) was used for statistical analyses. Differences with P#0.05
were considered statistically significant.
Results
A total of 384 patients (206 men, 178 women) with epilepsy
diagnoses who had received VPA treatment were identified.
Employing the data collection methods described above, 122
patients (64 men, 58 women) who met the inclusion criteria and
agreed to participate were included in the study. Subsequently,
four patients were excluded because of low serum VPA levels
measured during the evaluation visit (Figure 1). The final study
sample comprised 118 adult patients with epilepsy (63 men, 55
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women) and 493 control subjects (213 men, 280 women). Median
ages of the patients and control subjects were 32 years (IQR, 24–
45 years) and 47 years (IQR, 35–59 years), respectively. In recently
published studies, the mean reported increase of BMI after
initiation of VPA treatment in adults was around 2.5 kg/m2 [17–
22]. The power of the present study for detecting a BMI difference
of 2.5 kg/m2 with a SD of 5 is .90%. The clinical characteristics
of the patients are given in Table 1.
Seventy-one (60.2%) patients had generalized and 36 (30.5%)
had focal seizures; seizure type was unclear in 11 (9.3%) patients.
Sixty-four (54.3%) patients had been seizure-free for at least 1
year. The median duration of VPA treatment was 6 years (IQR,
2.5–10.0 years).
The crude prevalence of MS in adult patients with epilepsy who
received VPA monotherapy was 20.3% (95% CI, 13.7–28.9%);
this prevalence was 22.2% (95% CI, 13.1–34.8%) in men and
18.2% (95% CI, 9.5–31.4%) in women. The prevalence of MS in
VPA-treated patients, weighted by the age and sex distribution of
the control cohort, was 25.8% (95% CI, 18.4–34.8%). The
prevalence of MS in the control group was 27.9% (95% CI, 24.0–
Figure 1. Flowchart for the inclusion of valproate-treated patients with epilepsy.
doi:10.1371/journal.pone.0103856.g001
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32.1%). In the final multiple logistic regression, after adjustment
for age and sex, the risk of MS in VPA-treated patients was not
increased (OR = 1.00; 95% CI, 0.59–1.68; P = 0.998). However, a
larger proportion of VPA-treated patients had abnormal diastolic
BP ($85 mmHg) compared with control subjects (OR = 1.86; CI
1.15–3.03; P = 0.011; Table 2).
The clinical and biochemical characteristics of patients with and
without MS are shown in Table 3. Most (58.3%) patients with
epilepsy and MS had three components of the syndrome, 29.2%
had four components, and 12.5% had all five components. In
control subjects with MS, these percentages were 56.4%, 31.5%,
and 12.1%, respectively. Arterial hypertension (83.3%), abdominal
obesity (83.3%), and increased TG level (75.0%) were the most
common abnormalities in patients with epilepsy. In the control
subjects, the most common MS components were arterial
hypertension (93.6%), abdominal obesity (91.4%), and impaired
glucose metabolism (71.4%).
BMI did not differ between VPA-treated patients and control
subjects (P = 0.295); however, VPA-treated patients had higher
fasting serum insulin levels compared to control subjects (P,
0.0001). The HOMA-IR index was higher in patients than in
control subjects (P = 0.0001). These differences persisted when
only normal-weight subjects from both cohorts were compared
(P = 0.010 for insulin and P = 0.031 for HOMA-IR). Fasting
plasma glucose concentrations tended to be lower in patients than
in control subjects, although this difference was not significant
(P = 0.169). The HDL-C and TG levels were similar in patients
and control subjects (Table 4).
Logistic regression analysis showed no significant correlation
between MS development in VPA-treated patients and any clinical
characteristic, including age, sex, VPA dosage, HOMA-IR,
epilepsy etiology, seizure occurrence in the last year, and
subjectively reported weight gain during VPA treatment. Positive
correlations were found between MS development and BMI
(OR = 1.47; 95% CI, 1.25–1.73). Longer durations of VPA
treatment tended to increase the risk of MS, with borderline
statistical significance (OR = 1.01; 95% CI, 1.0–1.02). In over-
weight VPA-treated patients, the predictors of MS were HOMA-
IR (OR = 2.56; 95% CI, 1.40–4.70) and age (OR = 1.07; 95% CI,
1.01–1.13). In control subjects, MS development was correlated
positively with HOMA-IR (OR = 2.00; 95% CI, 1.61–2.49), BMI
(OR = 1.18; 95% CI, 1.12–1.24), and age (OR = 1.04; 95% CI,
1.02–1.06). ROC analysis showed that BMI and HOMA-IR
similarly predicted MS occurrence in control subjects, with areas
under the ROC curve (AUCs) of 0.847 and 0.848 (P = 0.97),
respectively (Figure 2). The predictive ability of HOMA-IR was
lower than that of BMI in VPA-treated patients, with AUCs of
0.808 and 0.897 (P = 0.050), respectively (Figure 3).
Discussion
In the past decade, increasing numbers of studies have
examined the adverse effects of VPA (e.g., weight gain, hyperin-
sulinemia, and endocrine abnormalities), reflecting growing
concern among physicians and patients who use this drug [23].
However, few studies have explored the potential relationship
between prolonged VPA treatment and MS in persons with
epilepsy [12,13]. For the first time, we demonstrated that the
prevalence of MS in adult patients with epilepsy who received
VPA treatment was 25.8%, which did not differ from the results of
a population-based study [11]. Because subjects in both cohorts
were drawn from the same population over the same extended
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habits were probably minimal, which makes the results even more
reliable.
The tendency of patients with epilepsy on long-term VPA
treatment to be overweight is generally recognized in the medical
community [19]. However, most studies examining weight gain
and abdominal obesity during VPA treatment have been incident
studies [17,20,21,24] or have used selected control subjects for
comparison [22]. Our results show that BMI is not higher in these
patients than in the general population. Our study design is the
main reason for these results, as patients whose VPA treatment
was discontinued due to side effects were not included in our
cohort. This design likely resulted in negative selection bias against
VPA-related side effects, such as weight gain. Nevertheless, the
study reflects the true clinical practice of medical VPA usage and
the management of VPA-related side effects in patients with
epilepsy.
A long duration of VPA therapy tended to increase the risk of
MS, but we found no correlation between daily VPA dosage and
Table 2. Logistic regression model for metabolic syndrome and its components in patients treated with valproate compared to
control subjects.
Component OR 95% CI P
Waist circumference 0.75 0.47–1.22 0.248
men, .102 cm 0.89 0.45–1.75 0.741
women, .88 cm 0.64 0.32–1.26 0.190
HDL-C 0.95 0.57–1.59 0.851
men, ,1.03 mmol/L 1.31 0.63–2.69 0.467
women, ,1.30 mmol/L 0.76 0.36–1.63 0.490
Triglycerides $1.7 mmol/L 1.34 0.80–2.24 0.267
Fasting glucose $5.6 mmol/L 0.78 0.46–1.31 0.352
Systolic blood pressure $130 mmHg 1.54 0.91–2.60 0.112
Diastolic blood pressure $85 mmHg 1.86 1.15–3.03 0.011
Metabolic syndrome 1.00 0.59–1.68 0.998
Odds ratios for metabolic syndrome and its components in valproate-treated patient cohort compared controls adjusted for age and sex.
doi:10.1371/journal.pone.0103856.t002
Table 3. Characteristics of subjects receiving valproate monotherapy with and without metabolic syndrome.
Characteristic Metabolic syndrome n = 24 No metabolic syndrome n = 94 P
Sex (male/female) 14/10 49/45 ,0.0001
Age (years) 44.6613.6 34.4615.4 ,0.001
Waist circumference (cm) 106.2610.4 82.3613.5 ,0.0001
Men 104.0610.1 88.7612.3 ,0.0001
Women 109.6610.5 75.6611.3 ,0.0001
Body mass index (kg/m2) 32.565.2 24.764.0 ,0.0001
Men 30.564.3 25.763.7 ,0.0001
Women 35.565.3 23.764.1 ,0.0001
HOMA-IR 3.9062.3 1.8561.3 ,0.0001
Men 3.862.4 2.161.4 ,0.01
Women 4.062.1 1.661.1 ,0.001
Systolic blood pressure (mmHg) 144.2623.8 120.5614.8 ,0.0001
Diastolic blood pressure (mmHg) 91.3611.6 78.5611.5 ,0.0001
Triglycerides (mmol/L) 2.461.3 1.160.5 ,0.0001
HDL-C - men (mmol/L) 1.160.3 1.460.4 ,0.0001
HDL-C - women (mmol/L) 1.260.2 1.860.5 ,0.0001
Fasting glucose (mmol/L) 5.761.2 5.060.5 ,0.001
Fasting insulin (mU/L) 16.0610.1 8.265.5 ,0.0001
Daily VPA dose (mg) 10606406 9396454 .0.05
VPA treatment duration (months) 128685 70658 ,0.01
Data presented as means 6 standard deviations.
VPA, valproate; HOMA-IR, homeostasis model assessment of insulin resistance.
doi:10.1371/journal.pone.0103856.t003
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Table 4. Anthropometric and laboratory data in the patients and control subjects.
Patients Control subjects P
BMI (kg/m2) 26.3865.34 28.1866.16 0.295
Fasting glucose (mmol/L) 5.1860.78 5.4360.82 0.169
Fasting insulin (mU/L) 9.1068.51 6.3565.52 ,0.0001
HOMA-IR 2.2162.01 1.6061.4 ,0.001
HDL-C (mmol/L) 1.5160.49 1.5360.45 0.581
Triglycerides (mmol/L) 1.3460.91 1.3160.72 0.375
Data presented as means 6 standard deviations.
BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance.
P values were calculated after comparison of parameters between cohorts using multiple linear regression model adjusted for age and sex.
doi:10.1371/journal.pone.0103856.t004
Figure 2. Receiver operating characteristic (ROC) curves of the homeostasis model assessment-estimated insulin resistance
(HOMA-IR) and body mass index (BMI) values in control subjects. BMI and HOMA-IR curves were obtained by logistic regression to
determine the probability of metabolic syndrome (MS) in control subjects. AUC, area under the curve.
doi:10.1371/journal.pone.0103856.g002
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MS development. These results are consistent with previous
reports showing a positive correlation between VPA treatment
duration and significant weight gain, and no influence of VPA
dosage [23]. Several studies reported that VPA-treated patients
exhibited hyperinsulinemia and a tendency toward lower plasma
glucose levels (reviewed by [3]), findings that were confirmed by
our results. The observation of these changes in both obese and
normal-weight patients suggests that hyperinsulinemia is the
leading factor for weight gain and MS development during VPA
treatment [25].
Lipid metabolism findings in VPA-treated patients have been
inconsistent. Some studies have associated VPA treatment with
decreased HDL-C [4] and increased TG [4,19,22] levels, whereas
others have found no effect of VPA treatment on lipid metabolism
[13,26]. One possible explanation is that VPA has no direct
influence on TG or HDL-C metabolism, in contrast to its effect on
insulin. Thus, the unfavorable changes in lipid levels probably
occur during the development of MS, the prevalence of which was
not increased among VPA-treated patients in our study. The
diversity of previously reported data on changes in lipid levels
during VPA treatment is probably related to differences in the
subject selection methods. Specifically, the lipid profiles are
probably more unfavorable in cohorts with higher proportions of
VPA-treated patients with MS.
Previous studies have paid little attention to the important side
effects of prolonged VPA treatment, such as a tendency towards
elevated BP [4,13]. This characteristic can be explained by the
increased serum insulin levels in VPA-treated patients, which can
lead to elevated sympathetic activity [27]. The increased
proportion of VPA-treated patients with high BP, in the absence
of differences in the prevalence of other MS components, suggests
that the tendency towards hypertension is a direct effect of VPA
Figure 3. Receiver operating characteristic (ROC) curves of the homeostasis model assessment-estimated insulin resistance
(HOMA-IR) and body mass index (BMI) values in valproate (VPA)-treated patients. BMI and HOMA-IR curves were obtained by logistic
regression to determine the probability of metabolic syndrome (MS) in patients treated with VPA. AUC, area under the curve.
doi:10.1371/journal.pone.0103856.g003
Valproate and Metabolic Syndrome
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e103856
treatment, probably due to hyperinsulinemia. Although MS did
not occur more frequently in our VPA-treated patients, the risks of
cardiovascular and cerebrovascular diseases may be increased,
given than hypertension is the leading cause of these conditions.
The pathophysiology of MS remains unclear, but many of its
features are associated with IR, which is typically defined as
decreased sensitivity or responsiveness to the metabolic action of
insulin [28]. The gold standard method for assessment of IR is the
hyperinsulinemic-euglycemic clamp technique originally devel-
oped by DeFronzo et al. [29]. As this method is complex and
unsuitable for epidemiological investigations, several surrogate
indices, such as the HOMA-IR index, have been developed.
Previous studies using the HOMA-IR index have reported the
presence of IR in patients receiving VPA treatment
[3,13,22,23,26]. However, an increased HOMA-IR index in these
patients most likely reflects hyperinsulinemia, which can occur in
obese and normal-weight patients. Pylvänen et al. [25] first raised
this issue and suggested that VPA interferes with insulin
degradation in the liver, resulting in higher insulin concentrations
in the peripheral circulation. In this case, an increased HOMA
value probably does not reflect reduced sensitivity to insulin.
Indeed, we found significantly higher HOMA indices in VPA-
treated patients than in control subjects, although the prevalence
of MS was similar in both cohorts. ROC analyses of the predictive
abilities of BMI and HOMA-IR for MS suggested that HOMA-IR
was an inferior predictor of MS in VPA-treated patients compared
to the general population. These results allow us to speculate that
previous studies applying the HOMA-IR index in VPA-treated
patients have probably overestimated the occurrence of IR.
The primary limitation of our study was the difference in age
distribution between cohorts. Age is an important determinant of
MS [30]. Patients with epilepsy were younger than control
subjects, as VPA is used mainly for the treatment of generalized
epilepsy, which usually manifests in children and young adults.
Because they were generally older, the subjects in the control
group might have been more likely to develop MS, causing a
negative bias against MS in the patient cohort. To overcome this
limitation, we used age- and sex-adjusted logistic regression
analysis, as well as indirect standardization.
Physical inactivity is another important risk factor for MS [30].
People with epilepsy tend to participate less often in physical
activities, as well as to have lower levels of endurance and
flexibility, compared to subjects without epilepsy [31]. However,
the physical activity levels of the patients and control subjects were
not assessed in the current study, which constitutes another
important limitation. Further studies should also compare the risk
of MS in people with epilepsy who take different antiepileptic
drugs as monotherapy. Considering these limitations, the results of
this study should be interpreted carefully. Given that the study
design focused on prevalence, the findings cannot be used to
indicate whether VPA causes weight gain. Nevertheless, we
observed that patients with epilepsy who received VPA treatment
were not more overweight than other people in our population.
In conclusion, we found that the risk of MS and increased body
weight was not greater in patients with epilepsy who had received
VPA treatment than in the general population. However, VPA-
treated patients had higher serum insulin concentrations, inde-
pendent of BMI, suggesting that hyperinsulinemia is not a
consequence of obesity. HOMA-IR had a lower predictive ability
for MS in patients who received VPA treatment compared to the
general population.
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